加载中........
×

MedSci 2017年期刊智能查询系统(2016年度)

期刊关键词: 支持模糊智能搜索,多关键词组合

期刊领域: 可留空

IF范围: 小于 大于 填数字,填写自己想选择的杂志影响' ;&+"vHE' ;&+"em>

排列方式: 文章数量往往与发表的周期有关

注册会员 86%用户已下载APP 如何高效使用?

    以下是对 CELL DEATH DIFFER 杂志介绍
    分享到:

    期刊名 cell death and differentiation 出版周期: 月刊

    常用链接 MedSci指数  |  中国SCI文章  |  杂志简介  |  杂志主页    | 投稿链接  | PMC链接 我要修改

    偏重的研究方向 细胞分化(2)  细胞信号(1)  细胞凋亡(1)  DNA repair(1)  死亡(1)  凋亡(1)  自噬(1)  细胞死亡(1)  我要补充

    审稿速度 平均1.5个月的审稿周期 投稿命中率 38.33%我要添加

    近四年影响因子 2016年度 2015年度 2014年度 2013年度 8.339 8.218 8.184 8.385 我要添加

    非自引影响因子 登录可见 | 5年影响因子: 登录可见 MedSci指数 12.767   |   5年指数9.1972

    中国人发表文章比例 需要登录可见 自引率 需要登录可见

    SCI期刊分区 大类:生物2区;小类:生化与分子生物学 2区 中科院JCR分区 大类:生物 1区[Top]; 小类: 生化与分子生物学 2区、细胞生物学 2区

    cell death and differentiation 投稿经验技巧分享
    31 条  首页 上一页 1 2 下一页 尾页 20条/页 寻求MedSci帮助

    李超斯

    请问结果如何一只苦逼科研狗 2017-02-11 发表::
    我投了五天就已经从under consideration 变成decision made ,是不是大事不妙。。。。

    2017-6-6 来自:梅斯医学APP(更精彩)

    (11)

    cedar

    今年还能达到8分吗

    2017-6-2

    (7)

    Forgetting

    2760/348=7.93

    2017-6-1

    (6)

    cedar

    谁知道Cell Death Differentiation 即时影响因子现在多少啊?预测能到8吗

    2017-5-9

    (6)

    sunnyphoenix

    同问,under consideration下一步是under review, 还是直接就给comments了,谢谢

    2017-4-14

    (11)

    cedar

    谁知道Cell Death Differentiation 即时影响因子现在多少啊?预测能到8吗

    2017-3-16

    (12)

    ambi

    谢谢~承诺 2016-02-23 发表::
    研究方向:DNA repair;; 接收率:约25% 审稿时间:约1个月 去年8月20投稿,第一次审稿40天,大修用去三个月,第二次审稿用去15天,修回用掉1个月,第三次审稿用去15天,修回用去一天,最后decision用了一天,到2016年2月20接收。刚好6个月。值得注意的是,CDD投稿须知中明白说了只有一次修回机会,第一次大修时着实压力巨大,一次机会而已,搞不好修回悲剧。只能说幸运,着实不容易。强调创新,注重图片质量。

    2017-3-6 来自:梅斯医学APP(更精彩)

    (19)

    ambi

    请问下,初稿的under consideration的下一阶段直接就是修回了麽?中间还有显示peer review的阶段麽?投了快一个月了,一直是under consideration,也不知道有没有送审承诺 2016-02-23 发表::
    研究方向:DNA repair;; 接收率:约25% 审稿时间:约1个月 去年8月20投稿,第一次审稿40天,大修用去三个月,第二次审稿用去15天,修回用掉1个月,第三次审稿用去15天,修回用去一天,最后decision用了一天,到2016年2月20接收。刚好6个月。值得注意的是,CDD投稿须知中明白说了只有一次修回机会,第一次大修时着实压力巨大,一次机会而已,搞不好修回悲剧。只能说幸运,着实不容易。强调创新,注重图片质量。

    2017-3-6 来自:梅斯医学APP(更精彩)

    (20)

    cedar

    现在这个杂志的影响因子多少啊今年能过8吗?谁知道啊

    2017-2-16

    (22)

    lee shshshsh

    结果如何?一只苦逼科研狗 2017-02-11 发表::
    我投了五天就已经从under consideration 变成decision made ,是不是大事不妙。。。。

    2017-2-16 来自:梅斯医学APP(更精彩)

    (16)

    一只苦逼科研狗

    我投了五天就已经从under consideration 变成decision made ,是不是大事不妙。。。。

    2017-2-11

    (20)

    princesun083

    我后来中了Molecular Therapy1875310****(暂无匿称) 2017-01-14 发表::
    请问你投的小CDD最后接受了吗?审稿周期大约多久呢,本人最近也在考虑这个杂志,希望借鉴点经验。

    2017-1-19 来自:梅斯医学APP(更精彩)

    (20)

    187****7090(暂无匿称)

    请问你投的小CDD最后接受了吗?审稿周期大约多久呢,本人最近也在考虑这个杂志,希望借鉴点经验。princesun083 2016-05-16 发表::
    4月22号投cell research,5月3号拒稿,建议转投Nature 其他刊物,于是5月5号同意转投CDD,今天收到拒稿信,建议转投小CDD,哎,一路拒,心都凉了,11个大图,4个组合补充图,1个正式表格,2个附加表格,数据量很足。心心念念想来 冲击10分以上,结果是这个结局。一下是转投小CDD的拒稿信。说是跟小CDD沟通了,转投会很快处理。 Thank you very much for submitting your manuscript to Cell Death and Differentiation (CDD). Cell Death & Differentiation mainly publishes original studies concerning the basic cellular and molecular mechanisms of cell death. Due to very limited space, we are forced to consider only papers which try to ' ;&+"vHE' ;&+"d phenomena. Unfortunately we can publish only a fraction of the manuscripts submitted to our journal, and therefore we aim to return the manuscripts that Editors feel are not appropriate as quickly as possible and without a time consuming and formal review. In each case, manuscripts are carefully evaluated by members of the Editorial Board. Papers may fall short of consideration on a number of editorial grounds. In this case both Editors felt that, although interesting, the topic covered by your study is too specific and has translational implications and would find a more appropriate readership in our specialized journal Cell Death & Disease. To be more precise, I have already discussed with Dr Raschellá, senior editor of Cell Death & Disease, who is available to personally receive it and decide how to best handle your manuscript. He is indeed waiting for your transfer to Cell Death & Disease Cell Death & Disease (impact factor above 5) is an author pays, open access, online only journal that levies an article-processing charge that you agree to pay, should your article be accepted, by transferring your manuscript to Cell Death & Disease. Decision will be very rapid. Please follow the link and select "Cell Death & Disease". I look forward to receiving your manuscript in "Cell Death & Disease" Thank you for considering our journal for the publication of your work. Yours sincerely, Richard Knight Receiving Editor Cell Death and Differentiation

    2017-1-14 来自:梅斯医学APP(更精彩)

    (21)

    nc98

    8月初投Cell Death & Differentiation,好像杂志有假期时间,现在还是under consideration状态,大概什么时候会有结果

    2016-8-29 下载:SCI期刊助手

    (32)

    princesun083

    4月22号投cell research,5月3号拒稿,建议转投Nature 其他刊物,于是5月5号同意转投CDD,今天收到拒稿信,建议转投小CDD,哎,一路拒,心都凉了,11个大图,4个组合补充图,1个正式表格,2个附加表格,数据量很足。心心念念想来 冲击10分以上,结果是这个结局。一下是转投小CDD的拒稿信。说是跟小CDD沟通了,转投会很快处理。
    Thank you very much for submitting your manuscript to Cell Death and Differentiation (CDD).

    Cell Death & Differentiation mainly publishes original studies concerning the basic cellular and molecular mechanisms of cell death. Due to very limited space, we are forced to consider only papers which try to address the above-mentioned phenomena. Unfortunately we can publish only a fraction of the manuscripts submitted to our journal, and therefore we aim to return the manuscripts that Editors feel are not appropriate as quickly as possible and without a time consuming and formal review. In each case, manuscripts are carefully evaluated by members of the Editorial Board. Papers may fall short of consideration on a number of editorial grounds. In this case both Editors felt that, although interesting, the topic covered by your study is too specific and has translational implications and would find a more appropriate readership in our specialized journal Cell Death & Disease.

    To be more precise, I have already discussed with Dr Raschellá, senior editor of Cell Death & Disease, who is available to personally receive it and decide how to best handle your manuscript. He is indeed waiting for your transfer to Cell Death & Disease

    Cell Death & Disease (impact factor above 5) is an author pays, open access, online only journal that levies an article-processing charge that you agree to pay, should your article be accepted, by transferring your manuscript to Cell Death & Disease. Decision will be very rapid. Please follow the link and select "Cell Death & Disease".


    I look forward to receiving your manuscript in "Cell Death & Disease"

    Thank you for considering our journal for the publication of your work.

    Yours sincerely,

    Richard Knight
    Receiving Editor
    Cell Death and Differentiation

    2016-5-16

    (27)

    jimwu

    请问一下,编辑的意见是转投cell death&disease,在哪里转投啊,怎么没有链接?

    2016-5-8 下载:SCI期刊助手

    (44)

    liuzhihao

    审稿时间:约2个月    接收率:约25%    
    谁能预测2016年影响因子

    2016-4-24 来自:梅斯医学APP(更精彩)

    (57)

    承诺

    研究方向:DNA repair     接收率:约25%    
    去年8月20投稿,第一次审稿40天,大修用去三个月,第二次审稿用去15天,修回用掉1个月,第三次审稿用去15天,修回用去一天,最后decision用了一天,到2016年2月20接收。刚好6个月。值得注意的是,CDD投稿须知中明白说了只有一次修回机会,第一次大修时着实压力巨大,一次机会而已,搞不好修回悲剧。只能说幸运,着实不容易。强调创新,注重图片质量。

    2016-2-23 下载:SCI期刊助手

    (39)

    xurongrong

    投稿40天后给修回意见,两个审稿人,一个很nice,一个特别苛刻。4个月返修,补得试验不多,但是,图片质量老说很差,如何处理?都是odyssey处理的结果图啊。

    2015-9-28 下载:SCI期刊助手

    (40)

    CR10

    2674/343=7.8

    2015-4-14 来自:梅斯医学APP(更精彩)

    (78)

    222.210.209.45

    同学,你说的CDD是cell death & DISEASE吧。虽然说Cell death & differentiation 影响力一般,但有些文章还是不错的。怎么说都比你说的“CDD”文章好不少啊。请把心放在你的研究上,不是Editor的这么关心杂志怎么样,有啥用?

    2014-3-13 来自:梅斯医学APP(更精彩)

    (110)
    31 条  首页 上一页 1 2 下一页 尾页 20条/页

      web对话
      live chat

      扫码领取IF曲线

      IF连续增长的期刊